City

Guangzhou (1)

Hangzhou (1)

Condition

PD1 (2)

Acute Myocardial Infarction (1)

Brain Tumor (1)

Breast Cancer (1)

CTLA4 (1)

Colo-rectal Cancer (1)

Liver Cancer (1)

Lung Cancer (1)

Solid Tumor, Adult (1)

Overall Status

Recruiting (2)

Sign in for free

Phase

phase 1 (1)

Sponsor

Second Affiliated Hospital of Guangzhou Medical University (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University (1)

Collaborator

First People's Hospital of Hangzhou (1)

Guangdong Zhaotai InVivo Biomedicine Co. Ltd. (1)

Intervention

pd1+ t cell expression (1)

tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3 (1)

Study Documents

Intervention Type

biological (2)

Funder Type

Other (2)

Study Type

Interventional (1)

Observational (1)

pd1

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

PD1+T Cell Expression in Peripheral Blood for Cardiac Function

Recruiting

PD1
Acute Myocardial Infarction

PD1+ T Cell Expression

Hangzhou, Zhejiang, China

The Second Affiliated Hospital of Zhejiang University, School of

Feb 22, 2022

Liver Cancer, Lung Cancer, Breast Cancer Trial in Guangzhou (TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y,

Recruiting

Liver Cancer
+7 more

TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3

Guangzhou, China

Second Affiliated Hospital of Guangzhou Medical University

Apr 9, 2021